GOCO · Gohealth, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $96.13M | $130.61M | $158.96M | $187.67M | $239.34M | $199.20M |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $90.79M | $82.12M | $93.07M | $116.53M | $98.18M | $197.23M |
| Total Operating Expenses | $774.75M | $805.94M | $816.35M | $950.34M | $1.55B | $941.90M |
| D&A | $9.56M | $11.83M | $11.69M | $12.95M | $13.45M | $4.50M |
| Operating Income | ($412.90M) | ($7.05M) | ($81.68M) | ($318.67M) | ($489.45M) | ($64.55M) |
| Interest Expense | $87.32M | $72.87M | $69.47M | $57.07M | $33.51M | $32.97M |
| Income Tax | ($3.33M) | $2.27M | $154.0K | $764.0K | ($24.0K) | $43.0K |
| Net Income | ($257.13M) | ($2.93M) | ($63.26M) | ($148.71M) | ($189.36M) | ($44.27M) |
| EPS - Basic | ($20.17) | ($0.66) | ($7.19) | ($17.72) | ($3.30) | - |
| EPS - Diluted | ($20.17) | ($0.66) | ($7.19) | ($17.72) | ($3.30) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.90M | $40.92M | $90.81M | $16.46M | $84.36M | $144.23M |
| Accounts Receivable | $72.0K | $4.45M | $250.0K | $4.70M | $17.28M | $26.87M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $6.92M | $14.59M | $17.70M | $15.15M | $39.84M | $8.73M |
| Current Assets | $285.79M | $400.41M | $476.44M | $414.56M | $429.00M | $391.82M |
| Total Assets | $987.38M | $1.49B | $1.50B | $1.66B | $2.07B | $2.11B |
| Current Liabilities | $141.50M | $338.05M | $370.01M | $265.45M | $217.07M | $127.37M |
| Long-term Debt | $636.74M | $447.87M | $422.70M | $504.81M | $665.12M | $396.40M |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $37.87M | $241.84M | $231.01M | $268.76M | $353.10M | $380.42M |
| Retained Earnings | ($680.33M) | ($423.21M) | ($420.28M) | ($357.02M) | ($208.32M) | ($18.80M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($121.95M) | ($21.61M) | $109.14M | $60.90M | ($299.01M) | ($114.22M) |
| Investing Cash Flow | ($8.25M) | $3.81M | ($13.73M) | ($13.51M) | ($19.80M) | ($14.52M) |
| Financing Cash Flow | $122.00M | ($32.03M) | ($21.11M) | ($115.05M) | $259.09M | $260.66M |
| CapEx | $8.25M | $13.73M | $13.73M | $13.51M | $19.80M | $14.52M |
| Free Cash Flow | ($130.19M) | ($35.34M) | $95.41M | $47.39M | ($318.81M) | ($128.74M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.51 | 12.07 | -1.51 | -0.32 | 1.68 | 2.91 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -26.0% | -0.2% | -4.2% | -9.0% | -9.2% | -2.1% |
| Return on equity | -678.9% | -1.2% | -27.4% | -55.3% | -53.6% | -11.6% |
| Return on invested capital | -48.4% | -0.8% | -9.9% | -32.5% | -38.0% | -6.6% |
| Liquidity | ||||||
| Current ratio | 2.02 | 1.18 | 1.29 | 1.56 | 1.98 | 3.08 |
| Quick ratio | 2.02 | 1.18 | 1.29 | 1.56 | 1.98 | 3.08 |
| Cash ratio | 0.23 | 0.12 | 0.25 | 0.06 | 0.39 | 1.13 |
| Leverage | ||||||
| Debt / Equity | 16.81 | 1.85 | 1.83 | 1.88 | 1.88 | 1.04 |
| Debt / Assets | 0.64 | 0.30 | 0.28 | 0.30 | 0.32 | 0.19 |
| Debt / EBITDA | - | 93.58 | - | - | - | - |
| Interest coverage | -4.7x | -0.1x | -1.2x | -5.6x | -14.6x | -2.0x |
| Equity multiplier | 26.07 | 6.15 | 6.49 | 6.17 | 5.86 | 5.54 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 26d | 41d | 41d | 29d | 61d | 16d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.7x | 0.6x | 0.5x | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | 112.9x | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -5759.2% | 91.4% | 74.4% | 34.9% | -658.3% | - |
| Net income growth (YoY) | -8681.6% | 95.4% | 57.5% | 21.5% | -327.8% | - |
| EPS growth (YoY) | -2956.1% | 90.8% | 59.4% | -437.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -268.4% | - | 101.3% | - | -147.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -84.3% | 4.7% | -14.0% | -23.9% | -7.2% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Insurance Agents, Brokers & Service
Comparing GoHealth against the 5 most active filers in the same SIC group.